Regeneron Pharmaceuticals Inc (NASDAQ:REGN) — Market Cap & Net Worth
Market Cap & Net Worth: Regeneron Pharmaceuticals Inc (REGN)
Regeneron Pharmaceuticals Inc (NASDAQ:REGN) has a market capitalization of $63.36 Billion ($63.36 Billion) as of June 16, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #443 globally and #228 in its home market, demonstrating a -3.22% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Regeneron Pharmaceuticals Inc's stock price $614.98 by its total outstanding shares 103021886 (103.02 Million). Review debt load of Regeneron Pharmaceuticals Inc to assess the company's total debt and financial obligations.
Regeneron Pharmaceuticals Inc Market Cap History: 2015 to 2026
Regeneron Pharmaceuticals Inc's market capitalization history from 2015 to 2026. Data shows growth from $55.93 Billion to $63.36 Billion (1.52% CAGR).
Index Memberships
Regeneron Pharmaceuticals Inc is a constituent of 7 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
ARCA Biotechnology
BTK
|
$918.18 Billion | 6.90% | #4 of 30 |
|
Dow Jones Biotechnology
DJUSBT
|
$1.08 Trillion | 5.86% | #5 of 39 |
|
S&P 500 Index
GSPC
|
$62.29 Trillion | 0.13% | #178 of 503 |
|
NASDAQ Health Care
IXHC
|
$2.44 Trillion | 2.60% | #6 of 976 |
|
NASDAQ Composite
IXIC
|
$41.39 Trillion | 0.15% | #69 of 3165 |
|
NASDAQ Biotechnology
NBI
|
$1.70 Trillion | 3.73% | #5 of 263 |
|
Nasdaq 100
NDX
|
$34.66 Trillion | 0.18% | #60 of 101 |
Weight: Regeneron Pharmaceuticals Inc's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Regeneron Pharmaceuticals Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Regeneron Pharmaceuticals Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
5.54x
Regeneron Pharmaceuticals Inc's market cap is 5.54 times its annual revenue
Latest Price to Earnings (P/E) Ratio
17.65x
Regeneron Pharmaceuticals Inc's market cap is 17.65 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $37.82 Billion | $4.86 Billion | $895.52 Million | 7.78x | 42.23x |
| 2017 | $38.73 Billion | $5.87 Billion | $1.20 Billion | 6.60x | 32.32x |
| 2018 | $38.48 Billion | $6.71 Billion | $2.44 Billion | 5.73x | 15.74x |
| 2019 | $38.68 Billion | $7.86 Billion | $2.12 Billion | 4.92x | 18.28x |
| 2020 | $49.77 Billion | $8.50 Billion | $3.51 Billion | 5.86x | 14.17x |
| 2021 | $65.06 Billion | $16.07 Billion | $8.08 Billion | 4.05x | 8.06x |
| 2022 | $74.33 Billion | $12.17 Billion | $4.34 Billion | 6.11x | 17.13x |
| 2023 | $90.48 Billion | $13.12 Billion | $3.95 Billion | 6.90x | 22.89x |
| 2024 | $73.39 Billion | $14.20 Billion | $4.41 Billion | 5.17x | 16.63x |
| 2025 | $79.52 Billion | $14.34 Billion | $4.50 Billion | 5.54x | 17.65x |
Competitor Companies of REGN by Market Capitalization
Companies near Regeneron Pharmaceuticals Inc in the global market cap rankings as of June 16, 2026.
Key companies related to Regeneron Pharmaceuticals Inc by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #222 globally with a market cap of $110.45 Billion USD.
- UCB SA (BR:UCB): Ranked #549 globally with a market cap of $49.68 Billion USD ( €42.50 Billion EUR).
- Argen-X (BR:ARGX): Ranked #574 globally with a market cap of $47.14 Billion USD ( €40.32 Billion EUR).
- argenx NV ADR (NASDAQ:ARGX): Ranked #589 globally with a market cap of $45.97 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #222 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $110.45 Billion | $450.46 |
| #549 | UCB SA | BR:UCB | $49.68 Billion | €259.20 |
| #574 | Argen-X | BR:ARGX | $47.14 Billion | €761.20 |
| #589 | argenx NV ADR | NASDAQ:ARGX | $45.97 Billion | $787.95 |
Regeneron Pharmaceuticals Inc Historical Marketcap From 2015 to 2026
Between 2015 and today, Regeneron Pharmaceuticals Inc's market cap moved from $55.93 Billion to $ 63.36 Billion, with a yearly change of 1.52%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $63.36 Billion | -20.33% |
| 2025 | $79.52 Billion | +8.36% |
| 2024 | $73.39 Billion | -18.90% |
| 2023 | $90.48 Billion | +21.73% |
| 2022 | $74.33 Billion | +14.25% |
| 2021 | $65.06 Billion | +30.72% |
| 2020 | $49.77 Billion | +28.66% |
| 2019 | $38.68 Billion | +0.53% |
| 2018 | $38.48 Billion | -0.65% |
| 2017 | $38.73 Billion | +2.42% |
| 2016 | $37.82 Billion | -32.38% |
| 2015 | $55.93 Billion | -- |
End of Day Market Cap According to Different Sources
On Jun 16th, 2026 the market cap of Regeneron Pharmaceuticals Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $63.36 Billion USD |
| MoneyControl | $63.36 Billion USD |
| MarketWatch | $63.36 Billion USD |
| marketcap.company | $63.36 Billion USD |
| Reuters | $63.36 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Regeneron Pharmaceuticals Inc
Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines to treat various diseases worldwide. The company develops product candidates to treat eye, allergic and inflammatory, cardiovascular, metabolic, neurological, infectious, and rare diseases; and cancer, hematologic conditions. It also offers EYLEA injections for wet age-related macular degenera… Read more